Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00679926 · ClinicalTrials.gov registry record · Phase 4
Kaletra and Viread in Antiretroviral Naïve Patients
A Phase 4 study, sponsored by Oklahoma State University Center for Health Sciences.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT00679926 is a Phase 4 study that was terminated before completion, run by Oklahoma State University Center for Health Sciences. The registered enrollment target is 6 participants.
The verdict
NCT00679926, a Phase 4 study, was terminated before completion, sponsored by Oklahoma State University Center for Health Sciences.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
Once daily antiretroviral therapy with Viread (tenofovir DF, 300mg) plus Kaletra (LPV/r, 800mg/200mg) will be effective in suppressing and maintaining suppression of HIV RNA to \<50 copies/ml in antiretroviral naïve patients through 48 weeks of therapy.
Interventions
- DRUG Once daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-05 |
| Est. Completion | 2011-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00679926
The ClinicalTrials.gov registry entry for NCT00679926 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oklahoma State University Center for Health Sciences, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Once daily is the first listed.
NCT00679926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00679926 about?
NCT00679926 is a clinical study titled "Kaletra and Viread in Antiretroviral Naïve Patients". Once daily antiretroviral therapy with Viread (tenofovir DF, 300mg) plus Kaletra (LPV/r, 800mg/200mg) will be effective in suppressing and maintaining suppression of HIV RNA to \<50 copies/ml in antiretroviral naïve patients through 48 weeks of therapy.
What is the current status of trial NCT00679926?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2008-05. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00679926?
The interventions under investigation include: Once daily (DRUG).
Who is sponsoring clinical trial NCT00679926?
This trial is sponsored by Oklahoma State University Center for Health Sciences, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.